Prior research has shown that most of the resistant tumours remain ERα-positive and critically dependent on activity of this signalling axis, with activating ESR1 gene mutations occurring in 15–40% of advanced cancers [4,5,6,7]. This evidence concerns the gene ESR1 and neoplasm.